Chaanakya Capital logoCHAANAKYA CAPITAL

Clinicians

The best neurotech filter is someone who has treated the patient.

Clinicians see the unmet need first. Chaanakya Capital brings that judgment into early-stage neurotech investing.

Why Chaanakya

  • Led with clinicians. Dr. Johana C.M. Vega Leonel and advisor Dr. Gerald A. Grant shape how we evaluate companies.

  • Patients over hype. We ask whether a device fits the clinical workflow, not only whether it works in a demo.

  • A network for clinician-founders. Many neurotech companies start in a clinic. We meet them early.

How to engage

Accredited clinicians can email hi@chaanakya.capital for the deck, or to ask about our low investment minimums. Clinician LPs can take on formal advisory and key-opinion-leader roles with us and our portfolio. Know a founder? Point them to submissions@chaanakya.capital.

hi@chaanakya.capital

Accredited investors only

Rule 506(c) offering

This is a Rule 506(c) offering available only to accredited investors. Accredited investor status must be verified before an investment is accepted.

Investing in private early-stage companies involves substantial risk, including loss of the entire investment, illiquidity, and a long investment horizon. There is no assurance of investment results. Nothing on this website is investment, legal or tax advice.

Chaanakya Capital's offering is made under Rule 506(c) of Regulation D and is open only to accredited investors whose status has been verified. Nothing on this website is an offer to sell, or a solicitation of an offer to buy, any security; any offer is made only through the fund's offering documents. Venture investing is high-risk and illiquid.

¹ Markups are unrealized. They include a personal angel investment made before the fund was formed; positions held by the fund also carry markups. Past performance is not indicative of future results.

Relevant questions